InVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation
Summary
InVivos core IP and expertise in CRISPR gene engineering in model organisms are helping accelerate drug discovery with both rapid turnaround and affordability. I am thrilled to support the InVivo Biosystems team alongside the other accomplished board members to realize the full potential of CRISPR capabilities in revolutionizing medical innovation for the 21st Century. This is particularly important for combining this technology with genome-edited fish that recapitulate human diseases, allowing for automated deep phenotyping that can aid in drug discovery efforts. With its CRISPR genome editing platform, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models for preclinical studies and drug discovery. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies to help accelerate decision-making in the early-stage development of new compounds.
Funding
Review available funding amount, funding date, investors, and linked company information related to InVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation in the interactive ISVWorld profile.